QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:SRRK

Scholar Rock - SRRK Stock Forecast, Price & News

$12.37
+0.14 (+1.14%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.83
$12.91
50-Day Range
$7.51
$12.72
52-Week Range
$4.32
$21.17
Volume
289,223 shs
Average Volume
354,486 shs
Market Capitalization
$639.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67

Scholar Rock MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.5% Upside
$25.67 Price Target
Short Interest
Bearish
5.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$455,061 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

495th out of 1,030 stocks

Biological Products, Except Diagnostic Industry

76th out of 169 stocks


SRRK stock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

Scholar Rock (NASDAQ:SRRK) Trading Up 4.2%
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Jay Backstrom is the new CEO at Scholar Rock
Expert Ratings for Scholar Rock Holding
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.67
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+107.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-131,800,000.00
Pretax Margin
-352.19%

Debt

Sales & Book Value

Annual Sales
$18.82 million
Book Value
$4.90 per share

Miscellaneous

Free Float
50,604,000
Market Cap
$639.03 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Edward H. Myles M.B.A.Mr. Edward H. Myles M.B.A. (Age 51)
    MBA, CFO, COO & Treasurer
    Comp: $615.87k
  • Dr. Jay T. Backstrom M.D. (Age 67)
    M.P.H., Pres, CEO & Director
  • Ms. Catherine Hu
    VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D. (Age 44)
    Gen. Counsel & Corp. Sec.
  • Ms. Caryn Parlavecchio (Age 51)
    Chief HR Officer
  • Ms. Lisa Amaya Price
    Sr. VP of HR
  • Dr. George G. Nomikos M.D.
    Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore (Age 48)
    Sr. VP of Fin.
  • Mr. Ryan Iarrobino
    Sr. VP of Clinical Devel. & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 58)
    M.D., Ph.D., Chief Medical Officer













SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for Scholar Rock's shares. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they expect the company's stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2023?

Scholar Rock's stock was trading at $9.05 on January 1st, 2023. Since then, SRRK stock has increased by 38.6% and is now trading at $12.54.
View the best growth stocks for 2023 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.13.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $12.54.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $647.82 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does Scholar Rock have?

The company employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 2/2/2023 by MarketBeat.com Staff